ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2026
Neuroprotective effects of pregabalin in experimental spinal cord injury: An investigation of oxidative stress and antioxidant enzymes in blood and neural tissue.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the neuroprotective potential of pregabalin (PB) and methylprednisolone (MP) in a rat model of spinal cord injury (SCI) by assessing serum and spinal cord levels of superoxide dismutase (SOD) and glutathione peroxidase (GPx), markers of oxidative stress, and neurological recovery outcomes.
methodsForty-four rats were randomized into six groups: sham, PB control (40 mg/kg), SCI alone, MP-treated SCI (30 mg/kg), and PB-treated SCI (40 and 80 mg/kg). SCI was induced at the T10 level using the Allen weight-drop method. PB and MP were administered intraperitoneally for three days post-injury. Neurological recovery was assessed using the Tarlov scale and inclined plane test. Although 44 rats were initially allocated, mortality and technical loss resulted in a final cohort of 35 animals; however, post hoc power remained >90% for key biochemical outcomes.
resultsSOD levels were significantly reduced in the MP+SCI group compared with the sham (p=0.006), SCI (p=0.015), 40 PB (p=0.004), and 80 PB+SCI (p=0.028) groups. Additionally, the SCI group exhibited lower SOD activity than the 40 PB group (p=0.007). Serum glutathione peroxidase levels were significantly lower in both the SCI (p=0.018) and 80 PB+SCI (p=0.009) groups compared with the sham group, whereas the 40 PB group showed higher GPx activity than the SCI (p=0.010) and 80 PB+SCI (p=0.006) groups. In spinal cord tissue, SOD activity in the 40 PB+SCI group was significantly lower than in the SCI group (p=0.007). Additionally, SOD activity in the SCI group was significantly higher than in the 40 PB group (p=0.007). Spinal cord GPx levels were significantly elevated in the SCI group compared with the sham (p=0.007), MP+SCI (p=0.010), 40 PB (p=0.003), 40 PB+SCI (p=0.003), and 80 PB+SCI (p=0.028) groups. Furthermore, the MP+SCI group demonstrated higher GPx activity than the sham group (p=0.045). Pregabalin improved inclined-plane performance but did not produce significant changes in Tarlov motor scores, indicating selective enhancement of postural stability rather than full locomotor recovery. Histopathological analysis revealed no significant differences between the trauma groups.
conclusionPregabalin mitigated oxidative stress and partially improved functional stability in experimental spinal cord injury, suggesting possible clinical applicability pending further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.